FI820856L - 2-fenoxialkyl-1,2,4-triazol-3-on antidepressiver - Google Patents

2-fenoxialkyl-1,2,4-triazol-3-on antidepressiver

Info

Publication number
FI820856L
FI820856L FI820856A FI820856A FI820856L FI 820856 L FI820856 L FI 820856L FI 820856 A FI820856 A FI 820856A FI 820856 A FI820856 A FI 820856A FI 820856 L FI820856 L FI 820856L
Authority
FI
Finland
Prior art keywords
phenoxialkyl
antidepressiver
triazol
Prior art date
Application number
FI820856A
Other languages
English (en)
Other versions
FI73670B (fi
FI73670C (fi
Inventor
Jr Davis L Temple
Jr Walter F Lobeck
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22922879&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI820856(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of FI820856L publication Critical patent/FI820856L/fi
Publication of FI73670B publication Critical patent/FI73670B/fi
Application granted granted Critical
Publication of FI73670C publication Critical patent/FI73670C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/067—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI820856A 1981-03-16 1982-03-12 Foerfarande foer framstaellning av nya terapeutiskt anvaendbara fenoxialkyl-1,2,4-triazol-3-on derivat. FI73670C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24446481 1981-03-16
US06/244,464 US4338317A (en) 1981-03-16 1981-03-16 Phenoxyethyl-1,2,4,-triazol-3-one antidepressants

Publications (3)

Publication Number Publication Date
FI820856L true FI820856L (fi) 1982-09-17
FI73670B FI73670B (fi) 1987-07-31
FI73670C FI73670C (fi) 1987-11-09

Family

ID=22922879

Family Applications (1)

Application Number Title Priority Date Filing Date
FI820856A FI73670C (fi) 1981-03-16 1982-03-12 Foerfarande foer framstaellning av nya terapeutiskt anvaendbara fenoxialkyl-1,2,4-triazol-3-on derivat.

Country Status (26)

Country Link
US (1) US4338317A (fi)
JP (1) JPS57159774A (fi)
KR (1) KR880001374B1 (fi)
AT (1) AT384022B (fi)
BE (1) BE892503A (fi)
CA (1) CA1198436A (fi)
CH (1) CH649539A5 (fi)
CY (1) CY1373A (fi)
DE (1) DE3209557A1 (fi)
DK (1) DK158728C (fi)
ES (1) ES8305756A1 (fi)
FI (1) FI73670C (fi)
FR (1) FR2501690B1 (fi)
GB (1) GB2096137B (fi)
GR (1) GR76076B (fi)
HK (1) HK4788A (fi)
IE (1) IE52788B1 (fi)
IT (1) IT1148137B (fi)
KE (1) KE3711A (fi)
LU (1) LU84011A1 (fi)
MX (1) MX9203176A (fi)
NL (2) NL190757C (fi)
SE (1) SE447256B (fi)
SG (1) SG30287G (fi)
YU (1) YU43256B (fi)
ZA (1) ZA821359B (fi)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487773A (en) * 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
US4386091A (en) * 1982-02-24 1983-05-31 Mead Johnson & Company 2-Phenoxyalkyl-1,2,4-triazol-3-one antidepressants
US4575555A (en) * 1983-06-29 1986-03-11 Mead Johnson & Company 4-(3-Chlorophenyl)-1,2,3,6-tetrahydropyridine derivative
AT388555B (de) * 1983-06-29 1989-07-25 Bristol Myers Co Verfahren zur herstellung von neuen 1,2,4-triazol-3-on-derivaten
US4613600A (en) * 1983-09-30 1986-09-23 Mead Johnson & Company Antidepressant 1,2,4-triazolone compounds
YU44721B (en) * 1983-11-30 1990-12-31 Bristol Myers Co Process for obtaining 4-(2-phenoxyethyl)-1,2,4-triazolone
CA1248531A (en) * 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
US4784998A (en) * 1987-04-06 1988-11-15 Bristol-Myers Company 1,3,4-oxadiazole pyschotropic compounds
US5116852A (en) * 1990-12-03 1992-05-26 Bristol-Myers Squibb Co. Treatment of sleep disorders
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
US5256664A (en) * 1992-04-28 1993-10-26 Bristol-Myers Squibb Company Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones
IT1256387B (it) * 1992-11-13 1995-12-04 Acraf Procedimento per preparare triazoloni
CA2160423A1 (en) * 1994-11-02 1996-05-03 Hemant N. Joshi Salts of nefazodone having improved dissolution rates
CA2187989A1 (en) 1995-10-17 1997-04-18 Ronald N. Marcus Nefazodone: treatment of panic attack
CA2182241C (en) * 1996-07-29 2002-09-17 Bo Lei Methods for the manufacture of nefazodone
WO1998004261A1 (en) * 1996-07-31 1998-02-05 Bristol-Myers Squibb Company Nefazodone: use in migraine prophylaxis
US5852020A (en) * 1996-11-22 1998-12-22 Bristol-Myers Squibb Company Nefazodone: use in treating post traumatic stress disorder
US5735873A (en) * 1996-12-19 1998-04-07 Maclean; David S. Surgical tool handle
US5917050A (en) * 1998-02-11 1999-06-29 Bayer Corporation Process for preparing alkoxytriazolinones
ES2152860B1 (es) 1998-10-23 2001-08-16 Finaf 92 Sa Forma cristalina de la nefazodona y procedimiento para su preparacion.
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
CA2369225A1 (en) 1999-04-09 2000-10-19 Sepracor Inc. S-hydroxynefazodone
ES2262515T3 (es) * 1999-04-09 2006-12-01 Sepracor Inc. R-hidroxinefazodona.
US6586437B2 (en) 1999-04-09 2003-07-01 Sepracor Inc. (S)-hydroxynefazodone antipsychotic therapy
US6469008B2 (en) 1999-04-09 2002-10-22 Sepracor Inc. (R)-hydroxynefazodone antipsychotic therapy
CA2356450C (en) 2001-09-10 2003-11-25 Brantford Chemicals Inc. An improved process for the preparation of nefazodone hydrochloride
DE50312523D1 (de) * 2002-05-24 2010-04-29 Carl-Fr Coester Pharmazeutische wirkstoffkombination sowie deren verwendung
GB0306604D0 (en) * 2003-03-21 2003-04-30 Curidium Ltd Second medical use
UA82875C2 (en) * 2003-04-30 2008-05-26 Insecticidal (dihalopropenyl) phenylalkyl substituted dihydrobenzofuran and dihydrobenzopyran derivatives and method for controlling insects
CA2547283C (en) * 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
TW200612961A (en) * 2004-05-18 2006-05-01 Fmc Corp Substituted cyclic urea derivatives
SG163588A1 (en) 2005-07-08 2010-08-30 Braincells Inc Methods for identifying agents and conditions that modulate neurogenesis
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
US20080171750A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation Of Neurogenesis With Use of Modafinil
US8222254B2 (en) * 2007-08-07 2012-07-17 Prosarix Limited 1, 2, 4-triazole derivatives as serotonergic modulators
US9339500B2 (en) 2008-03-04 2016-05-17 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
TWI368512B (en) * 2009-04-30 2012-07-21 Univ Kaohsiung Medical Pharmaceutical compositions comprising chlorophenyl piperazine derived compounds and use of the compounds in producing medicaments
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
CN104402842A (zh) * 2014-11-19 2015-03-11 苏州乔纳森新材料科技有限公司 一种哌嗪类药物中间体的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
IT1052119B (it) * 1972-10-16 1981-06-20 Sigma Tau Ind Farmaceuti Derivati del triazolinone e procedimento per la loro preparazione

Also Published As

Publication number Publication date
AT384022B (de) 1987-09-25
AU8117082A (en) 1982-09-23
AU555888B2 (en) 1986-10-16
US4338317A (en) 1982-07-06
LU84011A1 (fr) 1983-02-22
DE3209557A1 (de) 1982-12-09
ZA821359B (en) 1983-01-26
GR76076B (fi) 1984-08-03
CY1373A (en) 1987-08-07
GB2096137A (en) 1982-10-13
NL190757C (nl) 1994-08-01
KR830009089A (ko) 1983-12-17
NL970014I2 (nl) 1997-09-01
DK158728C (da) 1990-12-03
HK4788A (en) 1988-01-29
IE52788B1 (en) 1988-03-02
DK112582A (da) 1982-09-17
DK158728B (da) 1990-07-09
NL190757B (nl) 1994-03-01
SE8201631L (sv) 1982-09-17
FR2501690B1 (fr) 1985-07-05
FI73670B (fi) 1987-07-31
KR880001374B1 (ko) 1988-07-29
IT8247978A0 (it) 1982-03-12
DE3209557C2 (fi) 1993-07-15
IE820589L (en) 1982-09-16
FR2501690A1 (fr) 1982-09-17
NL8201021A (nl) 1982-10-18
YU52582A (en) 1985-06-30
YU43256B (en) 1989-06-30
SG30287G (en) 1987-07-17
CA1198436A (en) 1985-12-24
FI73670C (fi) 1987-11-09
CH649539A5 (de) 1985-05-31
ES510449A0 (es) 1983-04-16
IT1148137B (it) 1986-11-26
SE447256B (sv) 1986-11-03
ES8305756A1 (es) 1983-04-16
GB2096137B (en) 1985-01-03
ATA104582A (de) 1987-02-15
JPS57159774A (en) 1982-10-01
MX9203176A (es) 1992-07-01
NL970014I1 (nl) 1997-06-02
KE3711A (en) 1987-04-30
BE892503A (fr) 1982-09-15
JPH0237353B2 (fi) 1990-08-23

Similar Documents

Publication Publication Date Title
FI820856L (fi) 2-fenoxialkyl-1,2,4-triazol-3-on antidepressiver
MA19680A1 (fr) N- arylsulfonyl - n' - pyrimidinylurees.
FI831664L (fi) 1,3-dioxan-5-ylalkenoylsyror
DK165695C (da) 26,26,26,27,27,27-hexafluor-1alfa,25-dihydroxycholesterol
DK587183D0 (da) 1,4-benzodiazepin-derivater
FR2477145B1 (fr) 25-hydroxy-26, 26, 26, 27, 27, 27-hexafluorocholecalciferol
AR227553A1 (es) 3-bencilsulfonil-1-dietilcarbamoil-1,2,4-triazol
DK155594C (da) 3,3-dimethyl-1-phenoxybutan-2-oler
FI811967L (fi) 2,3-bis-hydroxibenzylderivat
MX9203211A (es) 6'-alquilespectinomicinas.
FI843110A (fi) 4'-halogenantracyklinglykosid.
DE3365097D1 (de) 6,7-dihydro-7,7-disubstituted-khellins
IT8349567A0 (it) 2,2,2-trialogeno-1-(trialogenometiletiliden-bis-benzen-tioli
FI812210L (fi) Stabiliserade 1,1,1-trikloretansammansaettningar
IT1152515B (it) 5-fenossifenil-tetraidro-1,3,5-tiadiazin-4-oni
DE3360666D1 (de) 2,6-dicyanoanilines
IT1189320B (it) 1-fenil-1,2,3-triazoli impiegabili come disappetenti
DE3175752D1 (de) 1,3-dihalopropan-2-ols
FI810242L (fi) 1,3-diformyloxi-2-brom-nitropropan
TR21560A (tr) Etilsulfonilmetil-i,3 ogzazolidin herbisid antidot
FI821159A0 (fi) 2,4-dioxacyclohexanonderivat
FI834384A (fi) Framstaellningsfoerfarande foer 4(5)- acetyl-2-metylimidazol.
ES264864Y (es) "pesacartas".
IT1156322B (it) Immidazo-e pirimido-1,3,5-tiadiazin-4-oni
FI824154A0 (fi) Foerfarande foer framstaellning av syrehaltiga 3,7a-diazacyklohepta/j,k/fluorenderivat

Legal Events

Date Code Title Description
TC Name/ company changed in patent

Owner name: BRISTOL-MYERS SQUIBB COMPANY

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L113

Extension date: 20070311

SPCL Withdrawal, rejection or dismissal of a supplementary protection certificate

Spc suppl protection certif: L113

MA Patent expired

Owner name: BRISTOL-MYERS SQUIBB COMPANY